Royal Bank of Canada
CTNM

Royal Bank of Canada’s Contineum Therapeutics CTNM Stock Holding History

Royal Bank of Canada’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76K Buy
5,794
+2,454
+73% +$32.9K ﹤0.01% 5281
2025
Q4 		$38K Buy
3,340
+511
+18% +$5.83K ﹤0.01% 5698
2025
Q3 		$33K Sell
2,829
-411
-13% -$3.31K ﹤0.01% 6010
2025
Q2 		$13K Buy
3,240
+2,976
+1,127% +$12.9K ﹤0.01% 6418
2025
Q1 		$2K Sell
264
-18,589
-99% -$169K ﹤0.01% 6606
2024
Q4 		$277K Buy
18,853
+17,630
+1,442% +$279K ﹤0.01% 4544
2024
Q3 		$22K Buy
1,223
+471
+63% +$9.03K ﹤0.01% 6079
2024
Q2 		$13K Buy
+752
New +$12.1K ﹤0.01% 6258

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Royal Bank of Canada's CTNM Position: Q1 2026 in Review

Royal Bank of Canada increased its Contineum Therapeutics (CTNM) stake by 73% in Q1 2026, buying an estimated $32.9K and bringing the position to 5,794 shares worth $76K. The position accounts for ﹤0.01% of the portfolio, ranked #5281.

Royal Bank of Canada first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. The position peaked at $277K in Q4 2024. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Royal Bank of Canada held 5,794 shares of Contineum Therapeutics worth $76K as of Q1 2026.
  • Royal Bank of Canada bought 2,454 Contineum Therapeutics shares in Q1 2026, an estimated $32.9K.
  • Contineum Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5281 holding.
  • Royal Bank of Canada first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Royal Bank of Canada's Contineum Therapeutics position peaked at $277K in Q4 2024.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.